Full Text View
Tabular View
No Study Results Posted
Related Studies
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH (CandLE)
This study has been completed.
Study NCT00607633   Information provided by AstraZeneca
First Received: January 23, 2008   Last Updated: February 5, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Essential Hypertension
Left Ventricular Hypertrophy
Additional conditions recognized in this trial
Hypertension
Hypertrophy
Hypertrophy, Left Ventricular
More general conditions related to this trial
Cardiomegaly
Cardiovascular Diseases
Heart Diseases
Pathological Conditions, Anatomical
Vascular Diseases
Additional drug interventions recognized in this trial
Candesartan
Candesartan cilexetil
Hydrochlorothiazide
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Cardiovascular Agents
Diuretics
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services